Get the Stockscreener App
1.34
13.56%
0.16
Geovax Labs Inc stock is traded at $1.34, with a volume of 636.32K.
It is up +13.56% in the last 24 hours and down -39.37% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
See More
Previous Close:
$1.18
Open:
$1.2
24h Volume:
636.32K
Relative Volume:
0.13
Market Cap:
$6.98M
Revenue:
$852.30K
Net Income/Loss:
$-21.37M
P/E Ratio:
-0.0618
EPS:
-21.6981
Net Cash Flow:
$-19.06M
1W Performance:
+13.56%
1M Performance:
-39.37%
6M Performance:
-77.68%
1Y Performance:
-94.20%
1-Day Range:
$1.1701
$1.38
1-Week Range:
$1.12
$1.47
52-Week Range:
$0.9631
$24.88
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.34 | 6.98M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
View All
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Labs Inc (GOVXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs, Inc. Files Form 8-K with SEC: Company Details, Address, and NASDAQ Listing Information - Minichart
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GeoVax Labs Inc (GOVXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs (GOVX) shareholders approve major warrant share issuances and governance items - Stock Titan
GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GeoVax Highlights Strategic Implications of Gedeptin for Checkpoint-Resistant Cancers - citybuzz -
GeoVax Labs Inc (GOVXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GeoVax Labs Inc (GOVXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GeoVax Labs Inc (GOVXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Labs Inc (GOVXW) Institutional Confidence - TradingKey
GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GOVX Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating LossAnnual Report - newsline.com
GOVX Q1 2026 Earnings: EPS Surprise of 41.89% as Loss Narrows from EstimatesConsensus Forecast Report - newsline.com
GeoVax Labs (GOVX) could find a support soon, here's why you should buy the stock now - MSN
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
GeoVax Labs Company Profile & Introduction - Moomoo
[SCHEDULE 13G] GeoVax Labs, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Why Is GOVX Stock Falling Today? - Stocktwits
Q3 2025 GeoVax Labs Inc Earnings Call Transcript - GuruFocus
GeoVax Highlights Research Showing Gedeptin Could Enhance Checkpoint Inhibitor Responses in Resistant Tumors - MEXC
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses - Yahoo Finance
GOVX Q1 2026 Earnings: EPS Surprises to the Upside, Yet Stock Retreats 11.8%EPS Surprise History - newsline.com
[EFFECT] GeoVax Labs, Inc. SEC Filing - Stock Titan
GeoVax Labs | EFFECT: Others - Moomoo
GOVX Technical Analysis | Trend, Signals & Chart Patterns | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
GeoVax CEO Sees Renewed Strategic Focus on Vaccine Platforms Amid Industry Acquisitions - citybuzz -
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation - Yahoo Finance
GeoVax CEO Highlights Biothreat Readiness as FIFA World Cup 2026 Approaches - MEXC
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness - Yahoo Finance
Why is GeoVax Labs stock falling Tuesday? - MSN
GOVX Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances DevelopmentEarnings Growth Forecast - newsline.com
GOVX: GEO-MVA advances to phase III with expedited EMA review, targeting unmet global vaccine demand - TradingView
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - Investing.com
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
GeoVax CEO to Discuss Platform-Based Vaccine Technologies in Tribe Public Webinar - citybuzz -
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event - NewMediaWire
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW! - marketscreener.com
GOVX Q1 2026 Earnings: Narrower-than-Expected Loss Surprises MarketTech Earnings Analysis - The Legal Advocate
GeoVax Labs (GOVX) Narrows Focus on Key Development Programs - GuruFocus
GOVX Faces 11% Decline Following Suspension of COVID Vaccine Ini - GuruFocus
GeoVax Labs (GOVX) Shifts Focus from COVID Vaccine to Smallpox P - GuruFocus
GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development - citybuzz -
GeoVax (GOVX) resale S-1 shows 7.6M warrant shares and tight cash runway - Stock Titan
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R) - Yahoo Finance
How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks - Yahoo Finance
Roth MKM Maintains GeoVax Labs(GOVX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
GOVX Q1 2026 Earnings: Narrower Loss Surprises, Shares Surge Over 32%Earnings Call Q&A - The Legal Advocate
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):